234 related articles for article (PubMed ID: 37439373)
21. Inflammation in Sickle Cell Disease: Differential and Down-Expressed Plasma Levels of Annexin A1 Protein.
Torres LS; Okumura JV; Silva DG; Mimura KK; Belini-Júnior É; Oliveira RG; Lobo CL; Oliani SM; Bonini-Domingos CR
PLoS One; 2016; 11(11):e0165833. PubMed ID: 27802331
[TBL] [Abstract][Full Text] [Related]
22. Treatment of sickle cell anemia with hydroxyurea and erythropoietin.
Goldberg MA; Brugnara C; Dover GJ; Schapira L; Charache S; Bunn HF
N Engl J Med; 1990 Aug; 323(6):366-72. PubMed ID: 1695325
[TBL] [Abstract][Full Text] [Related]
23. Interventions for preventing silent cerebral infarcts in people with sickle cell disease.
Estcourt LJ; Fortin PM; Hopewell S; Trivella M; Doree C; Abboud MR
Cochrane Database Syst Rev; 2017 May; 5(5):CD012389. PubMed ID: 28500860
[TBL] [Abstract][Full Text] [Related]
24. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
[TBL] [Abstract][Full Text] [Related]
25. Red blood cells microparticles are associated with hemolysis markers and may contribute to clinical events among sickle cell disease patients.
Olatunya OS; Lanaro C; Longhini AL; Penteado CFF; Fertrin KY; Adekile A; Saad STO; Costa FF
Ann Hematol; 2019 Nov; 98(11):2507-2521. PubMed ID: 31493004
[TBL] [Abstract][Full Text] [Related]
26. Longitudinal effect of disease-modifying therapy on tricuspid regurgitant velocity in children with sickle cell anemia.
Rai P; Joshi VM; Goldberg JF; Yates AM; Okhomina VI; Penkert R; Ataga KI; Kang G; Hankins JS
Blood Adv; 2021 Jan; 5(1):89-98. PubMed ID: 33570630
[TBL] [Abstract][Full Text] [Related]
27. Intravenous infusion of haptoglobin for the prevention of adverse clinical outcome in Sickle Cell Disease.
Quimby KR; Hambleton IR; Landis RC
Med Hypotheses; 2015 Oct; 85(4):424-32. PubMed ID: 26141635
[TBL] [Abstract][Full Text] [Related]
28. Hydroxyurea and erythropoietin therapy in sickle cell anemia.
Goldberg MA; Brugnara C; Dover GJ; Schapira L; Lacroix L; Bunn HF
Semin Oncol; 1992 Jun; 19(3 Suppl 9):74-81. PubMed ID: 1379376
[TBL] [Abstract][Full Text] [Related]
29. Sickle cell disease: A distinction of two most frequent genotypes (HbSS and HbSC).
da Guarda CC; Yahouédéhou SCMA; Santiago RP; Neres JSDS; Fernandes CFL; Aleluia MM; Figueiredo CVB; Fiuza LM; Carvalho SP; Oliveira RM; Fonseca CA; Ndidi US; Nascimento VML; Rocha LC; Goncalves MS
PLoS One; 2020; 15(1):e0228399. PubMed ID: 31995624
[TBL] [Abstract][Full Text] [Related]
30. Neurocognitive functioning in preschool children with sickle cell disease.
Heitzer AM; Cohen DL; Okhomina VI; Trpchevska A; Potter B; Longoria J; Porter JS; Estepp JH; King A; Henley M; Kang G; Hankins JS
Pediatr Blood Cancer; 2022 Mar; 69(3):e29531. PubMed ID: 34971013
[TBL] [Abstract][Full Text] [Related]
31. Effect of hydroxyurea therapy on intravascular hemolysis and endothelial dysfunction markers in sickle cell anemia patients.
Chenou F; Hounkpe BW; Domingos IF; Tonassé WV; Batista THC; Santana RM; Arcanjo GDS; Alagbe AE; Araújo ADS; Lucena-Araújo AR; Bezerra MAC; Costa FF; Sonati MF; De Paula EV; Dos Santos MNN
Ann Hematol; 2021 Nov; 100(11):2669-2676. PubMed ID: 34453189
[TBL] [Abstract][Full Text] [Related]
32. A Multidimensional Electronic Hydroxyurea Adherence Intervention for Children With Sickle Cell Disease: Single-Arm Before-After Study.
Creary S; Chisolm D; Stanek J; Hankins J; O'Brien SH
JMIR Mhealth Uhealth; 2019 Aug; 7(8):e13452. PubMed ID: 31397291
[TBL] [Abstract][Full Text] [Related]
33. Sickle cell disease; a general overview.
Schnog JB; Duits AJ; Muskiet FA; ten Cate H; Rojer RA; Brandjes DP
Neth J Med; 2004 Nov; 62(10):364-74. PubMed ID: 15683091
[TBL] [Abstract][Full Text] [Related]
34. Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease.
Rodgers GP; Dover GJ; Uyesaka N; Noguchi CT; Schechter AN; Nienhuis AW
N Engl J Med; 1993 Jan; 328(2):73-80. PubMed ID: 7677965
[TBL] [Abstract][Full Text] [Related]
35. Novel approaches to the treatment of sickle cell disease: the potential of histone deacetylase inhibitors.
Okam MM; Ebert BL
Expert Rev Hematol; 2012 Jun; 5(3):303-11. PubMed ID: 22780210
[TBL] [Abstract][Full Text] [Related]
36. Systemic medications for sickle cell disease and potential applications for sickle cell retinopathy.
Garg AK; Scott AW
Curr Opin Ophthalmol; 2024 May; 35(3):185-191. PubMed ID: 38465910
[TBL] [Abstract][Full Text] [Related]
37. Hydroxyurea improves nitric oxide bioavailability in humanized sickle cell mice.
Taylor CM; Kasztan M; Sedaka R; Molina PA; Dunaway LS; Pollock JS; Pollock DM
Am J Physiol Regul Integr Comp Physiol; 2021 May; 320(5):R630-R640. PubMed ID: 33624556
[TBL] [Abstract][Full Text] [Related]
38. Associations of Prolonged QTc in Sickle Cell Disease.
Indik JH; Nair V; Rafikov R; Nyotowidjojo IS; Bisla J; Kansal M; Parikh DS; Robinson M; Desai A; Oberoi M; Gupta A; Abbasi T; Khalpey Z; Patel AR; Lang RM; Dudley SC; Choi BR; Garcia JG; Machado RF; Desai AA
PLoS One; 2016; 11(10):e0164526. PubMed ID: 27736922
[TBL] [Abstract][Full Text] [Related]
39. cGMP modulation therapeutics for sickle cell disease.
Conran N; Torres L
Exp Biol Med (Maywood); 2019 Feb; 244(2):132-146. PubMed ID: 30691292
[TBL] [Abstract][Full Text] [Related]
40. Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review.
Little JA; McGowan VR; Kato GJ; Partovi KS; Feld JJ; Maric I; Martyr S; Taylor JG; Machado RF; Heller T; Castro O; Gladwin MT
Haematologica; 2006 Aug; 91(8):1076-83. PubMed ID: 16885048
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
